Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Must have a confirmed diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS), and a cranial magnetic resonance imaging (MRI) demonstrating lesion(s) consistent with MS~* Must have a baseline Expanded Disability Status Scale (EDSS) between 0.0 and 5.0, inclusive~* Male subjects and female subjects of childbearing potential must be willing to practice effective contraception during the study and be willing and able to continue contraception for 4 months after their last dose of study treatment~Key Exclusion Criteria:~* Known intolerance, contraindication to, or history of non-compliance with Avonex® 30 µg~* History of treatment with Daclizumab High Yield Process (Dac HYP)~* History of malignancy~* History of severe allergic or anaphylactic reactions~* Known hypersensitivity to study drugs or their excipients~* History of abnormal laboratory results indicative of any significant disease~* History of human immunodeficiency virus (HIV) or other immunodeficient conditions~* History of drug or alcohol abuse (as defined by the Investigator) within the 2 years prior to randomization~* History of seizure disorder or unexplained blackouts OR history of a seizure within 6 months prior to Baseline~* History of suicidal ideation or an episode of clinically severe depression (as determined by the Investigator) within 3 months prior to Day 1~* An MS relapse that has occurred within the 50 days prior to randomization AND/OR the subject has not stabilized from a previous relapse prior to randomization~* Known history of, or positive screening test result for hepatitis C virus or hepatitis B virus~* Varicella or herpes zoster virus infection or any severe viral infection within 6 weeks before screening~* Exposure to varicella zoster virus within 21 days before screening~NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Daclizumab High Yield Process 150 mg SC (Type: EXPERIMENTAL): Daclizumab High Yield Process (DAC HYP) 150mg subcutaneous (SC) injection once every 4 weeks plus placebo to IFN β-1a intramuscular (IM) injection once weekly for 96 to 144 weeks
- IFN β-1a 30 µg IM (Type: ACTIVE_COMPARATOR): Interferon beta-1a (IFN β-1a) 30 µg IM once weekly plus placebo to DAC HYP SC once every 4 weeks for 96 to 144 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).